Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis

doi:10.12998/wjcc.v7.i12.1367

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6592)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

535

WORD

359

HTML

2918

Tables (1-4)

339

Sum=4151

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

963

Download

1478

Sum=2441

Jun 26, 2019 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Cases. Jun 26, 2019; 7(12): 1367-1382
Published online Jun 26, 2019. doi: 10.12998/wjcc.v7.i12.1367

Table 2 International guidelines for hepatocellular carcinoma diagnosis

Guideline	Liver nodule US	Biomarkers	Indications for biomarkers
Canadian	CT/MRI/CEUS	AFP, AFP-L3, DCP	Late stage/aggressive
AASLD	CT/MRI
ACG	CT/MRI
NCCN	CT/MRI
Australian	CT/MRI/CEUS: Selected case
EASL	CT/MRI/CEUS
ESMO	CT/MRI
Japan	CT/MRI	AFP, AFP-L3, DCP	Definitive diagnosis, efficacy of treatment
Asia-Pacific	CT/MRI/CEUS

AFP: Alpha-fetoprotein; AFP-L3: Alpha-fetoprotein L3; AASLD: American Association for the Study of Liver Diseases; CEUS: Contrast-enhanced computed tomography; CT: Computed tomography; DCP: Des-gamma-carboxyprothrombin; EASL: European Association for the Study of the Liver; ESMO: European Society for Medical Oncology; MRI: Magnetic resonance imaging; NCCN: National Comprehensive Cancer Network; US: Ultrasonography.

Citation: Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382
URL: https://www.wjgnet.com/2307-8960/full/v7/i12/1367.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i12.1367